Developer docs
API playgroundTry for free, no card

Search company profiles

K2 HealthVentures

Full company profile

uuid0007142

Namestring
K2 HealthVentures
Legal namestring
K2 HealthVentures
Company typeenum
Private
Founded yearint
2018
Descriptiontext

K2 HealthVentures is a Boston-based private alternative investment firm that provides flexible, long-term financing solutions to private and public companies in the life sciences and healthcare industries. The firm was founded in 2018 and, per its website, has assembled over $1.5 billion in capital commitments since inception, with its leadership team having collectively committed more than $4 billion across more than 100 portfolio companies over their careers.

The firm operates three primary investment vehicles: customized debt financing solutions (its primary focus), equity investments, and convertible securities. Its debt facilities are typically structured with milestone-based tranches tied to clinical, regulatory, or commercial events, enabling portfolio companies to fund late-stage development, manufacturing scale-up, and commercial launch planning without significant equity dilution. The firm describes its capital base as a "permanent capital structure" that supports multi-year, multi-tranche commitments.

K2 HealthVentures deploys capital through a relationship-driven, enterprise field sales model, sourcing transactions via direct outreach, investment submissions, and co-investor partnerships with firms such as Piper Sandler, NewSpring Healthcare, Rubicon Founders, Oak HC/FT, General Catalyst, and Healthier Capital. Recent activity spans clinical-stage biotech (Cartesian Therapeutics, Neumora Therapeutics), value-based care (Honest Health, Evergreen Nephrology), specialty care (Zarminali Pediatrics), healthcare technology (Apella, Kandu), and pharmaceutical commercialization (Phil). The firm is led by founders Parag Shah (Managing Director & CEO) and Anup Arora (Managing Director & CIO), supported by a team of under 50 professionals including managing directors, vice presidents, and a CFO-style operations lead.

Short descriptiontext

K2 HealthVentures is a Boston-based private alternative investment firm founded in 2018 that provides customized debt, equity, and convertible financing to private and public healthcare and life sciences companies, with over $1.5 billion in capital commitments since inception.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersBoston, United States
HQ citystring
Boston
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
healthcare debt financing, life sciences investment, venture debt solutions, alternative investment firm, healthcare growth capital
Industry2 codes
PRIMARYFSANAIAB
Independent Venture Debt Funds / Platforms
SECONDARYFSANACAD
Business Services (B2B) Growth Equity
NAICS code1 code
  • Funds, Trusts, and Other Financial Vehicles525
SIC code1 code
  • Short-Term Business Credit Institutions6153
Product category
Healthcare and Life Sciences Investment Services
No data
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Debt Financing Returns
TypeSubscription Recurring
Description

K2 HealthVentures generates returns through interest payments on customized debt facilities provided to healthcare companies. The firm structures credit facilities with milestone-based tranches that generate recurring interest income.

k2hv.com
2Equity Investment Returns
TypeSubscription Recurring
Description

Returns from equity investments and convertible instruments in portfolio companies through value appreciation and potential exit events.

k2hv.com
Marketing channels1 record

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Operations, Technology or R&D, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

K2 HealthVentures provides flexible, long-term financing solutions to innovative private and public companies in the life sciences and healthcare industries. Its primary vehicle is customized debt financings structured with milestone-based tranches tied to clinical, regulatory, and commercial milestones, complemented by the ability to invest in equity and convertible securities under a broad investment mandate.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

K2 HealthVentures is an alternative investment firm offering flexible, long-term financing solutions to innovative companies in the life sciences and healthcare industries. The firm operates three primary investment products: Debt Financing Solutions (their primary focus providing customized debt facilities), Equity Investments, and Convertible Securities. Their uniquely flexible, permanent capital structure enables them to provide creative financing structures tailored to meet the evolving capital needs of growing companies throughout their lifecycles.

Product and service3 records
1Debt Financing Solutions
CategoryDebt Financing
Description

Customized debt financing facilities provided to private and public companies in the life sciences and healthcare industries, structured around clinical, approval, and commercial milestones. Designed to deliver non-dilutive capital while preserving shareholder equity.

2Equity Investments
CategoryEquity Investment
Description

Equity capital investments in healthcare and life sciences companies, typically deployed alongside debt as part of flexible financing packages for growing companies.

3Convertible Securities
Scale indicator9 records

Each record includes

Type, Value, Description, Source

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Horizon Technology Finance is a specialty finance company providing venture debt to development-stage companies in life sciences and technology. Overlapping mandate with K2HV in life sciences venture lending makes it a direct peer.

TypeBroad incumbent
Description

OrbiMed is one of the largest global healthcare-dedicated investment firms, offering private equity, credit, and royalty financing across all stages of healthcare and life sciences. Comparable to K2HV in healthcare specialization but operates at significantly broader scale and product breadth.

TypeBroad incumbent
Description

SVB was historically the dominant venture debt provider to US startups including healthcare, now operating under First Citizens Bank. Comparable as a broad incumbent in venture debt with significant healthcare exposure, but serves a much wider customer base beyond healthcare.

TypeDirect peer
Description

Oxford Finance is a specialty finance firm providing senior secured loans to life sciences and healthcare companies. Its exclusive healthcare/life sciences focus and customized debt structures make it a direct comparable to K2HV.

TypeDirect peer
Description

Hercules Capital is the largest publicly traded specialty finance company focused on venture debt to venture- and growth-stage companies, with a heavy emphasis on life sciences and technology. It is the closest direct peer to K2HV in mandate, structure, and target customer.

6SLR Capital Partners / SLR Healthcare ABL
TypeDirect peer
Description

SLR Healthcare ABL provides asset-based and venture debt financing to healthcare companies across multiple sub-sectors. Directly comparable to K2HV in providing flexible debt capital to healthcare growth and innovation-stage companies.

TypeDirect peer
Description

Innovatus Capital Partners is an alternative investment manager providing debt and equity capital solutions to healthcare and technology companies, including structured venture debt — directly comparable in healthcare-focused debt offerings and patient-capital orientation.

TypeDirect peer
Description

Runway Growth Finance provides senior debt to growth-stage companies across healthcare and technology, often partnering with VC sponsors. Overlapping strategy in growth-stage debt for healthcare companies makes it a direct peer.

TypeDirect peer
Description

Trinity Capital provides venture debt and equipment financing to growth-stage companies, with a notable healthcare and life sciences vertical. Comparable to K2HV in customer segment (healthcare growth companies) and product (customized debt facilities).

TypeBroad incumbent
Description

Perceptive Advisors is a healthcare-focused investment firm managing credit, venture, and public equity strategies. Comparable in healthcare specialization and credit-oriented product offering, though substantially larger and more diversified.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment66 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

K2 HealthVentures

Healthcare and Life Sciences Investment Servicesk2healthventures.com

K2 HealthVentures is a Boston-based private alternative investment firm founded in 2018 that provides customized debt, equity, and convertible financing to private and public healthcare and life sciences companies, with over $1.5 billion in capital commitments since inception.

What K2 HealthVentures does

K2 HealthVentures is a Boston-based private alternative investment firm that provides flexible, long-term financing solutions to private and public companies in the life sciences and healthcare industries. The firm was founded in 2018 and, per its website, has assembled over $1.5 billion in capital commitments since inception, with its leadership team having collectively committed more than $4 billion across more than 100 portfolio companies over their careers.

The firm operates three primary investment vehicles: customized debt financing solutions (its primary focus), equity investments, and convertible securities. Its debt facilities are typically structured with milestone-based tranches tied to clinical, regulatory, or commercial events, enabling portfolio companies to fund late-stage development, manufacturing scale-up, and commercial launch planning without significant equity dilution. The firm describes its capital base as a "permanent capital structure" that supports multi-year, multi-tranche commitments.

K2 HealthVentures deploys capital through a relationship-driven, enterprise field sales model, sourcing transactions via direct outreach, investment submissions, and co-investor partnerships with firms such as Piper Sandler, NewSpring Healthcare, Rubicon Founders, Oak HC/FT, General Catalyst, and Healthier Capital. Recent activity spans clinical-stage biotech (Cartesian Therapeutics, Neumora Therapeutics), value-based care (Honest Health, Evergreen Nephrology), specialty care (Zarminali Pediatrics), healthcare technology (Apella, Kandu), and pharmaceutical commercialization (Phil). The firm is led by founders Parag Shah (Managing Director & CEO) and Anup Arora (Managing Director & CIO), supported by a team of under 50 professionals including managing directors, vice presidents, and a CFO-style operations lead.

K2 HealthVentures firmographics

Firmographics
Name
K2 HealthVentures
Legal name
K2 HealthVentures
Website
https://k2healthventures.com
Company type
Private
Founded year
2018
Operating status
Operating
Headcount range
11–50 employees
Short description
K2 HealthVentures is a Boston-based private alternative investment firm founded in 2018 that provides customized debt, equity, and convertible financing to private and public healthcare and life sciences companies, with over $1.5 billion in capital commitments since inception.
Ownership category
akta.pro rank

K2 HealthVentures industry classification

Industry
Product category
Healthcare and Life Sciences Investment Services
NAICS
Funds, Trusts, and Other Financial Vehicles (525)
SIC
Short-Term Business Credit Institutions (6153)
akta.pro industry
PRIMARYFSANAIAB
Independent Venture Debt Funds / Platforms
SECONDARYFSANACAD
Business Services (B2B) Growth Equity

Keywords

  • Healthcare debt financing
  • Life sciences investment
  • Venture debt solutions
  • Alternative investment firm
  • Healthcare growth capital

Where K2 HealthVentures is headquartered

Location

Headquarters

HQ city
Boston
HQ country
United States
HQ region
North America

Markets served

K2 HealthVentures business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Marketing or Sales

Revenue model

  1. Debt Financing Returns: K2 HealthVentures generates returns through interest payments on customized debt facilities provided to healthcare companies. The firm structures credit facilities with milestone-based tranches that generate recurring interest income.
  2. Equity Investment Returns: Returns from equity investments and convertible instruments in portfolio companies through value appreciation and potential exit events.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels1 record

K2 HealthVentures product offering

Product offering

Core offering

K2 HealthVentures provides flexible, long-term financing solutions to innovative private and public companies in the life sciences and healthcare industries. Its primary vehicle is customized debt financings structured with milestone-based tranches tied to clinical, regulatory, and commercial milestones, complemented by the ability to invest in equity and convertible securities under a broad investment mandate.

Product overview

K2 HealthVentures is an alternative investment firm offering flexible, long-term financing solutions to innovative companies in the life sciences and healthcare industries. The firm operates three primary investment products: Debt Financing Solutions (their primary focus providing customized debt facilities), Equity Investments, and Convertible Securities. Their uniquely flexible, permanent capital structure enables them to provide creative financing structures tailored to meet the evolving capital needs of growing companies throughout their lifecycles.

Differentiator

Problem solved

Functional benefit

Products and services

  • Debt Financing Solutions Customized debt financing facilities provided to private and public companies in the life sciences and healthcare industries, structured around clinical, approval, and commercial milestones. Designed to deliver non-dilutive capital while preserving shareholder equity.
  • Equity Investments Equity capital investments in healthcare and life sciences companies, typically deployed alongside debt as part of flexible financing packages for growing companies.
  • Convertible Securities

Companies that use K2 HealthVentures

Customer profile

Segments3 records

Ideal customer profiles2 records

K2 HealthVentures technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

K2 HealthVentures partnerships and signals

Strategic signal

Scale indicators9 records

Recent moves6 records

Expansion highlights5 records

K2 HealthVentures competitors and assessment

Company assessment

Direct peers

  • Horizon Technology Finance: Horizon Technology Finance is a specialty finance company providing venture debt to development-stage companies in life sciences and technology. Overlapping mandate with K2HV in life sciences venture lending makes it a direct peer.
  • Oxford Finance: Oxford Finance is a specialty finance firm providing senior secured loans to life sciences and healthcare companies. Its exclusive healthcare/life sciences focus and customized debt structures make it a direct comparable to K2HV.
  • Hercules Capital: Hercules Capital is the largest publicly traded specialty finance company focused on venture debt to venture- and growth-stage companies, with a heavy emphasis on life sciences and technology. It is the closest direct peer to K2HV in mandate, structure, and target customer.
  • SLR Capital Partners / SLR Healthcare ABL: SLR Healthcare ABL provides asset-based and venture debt financing to healthcare companies across multiple sub-sectors. Directly comparable to K2HV in providing flexible debt capital to healthcare growth and innovation-stage companies.
  • Innovatus Capital Partners: Innovatus Capital Partners is an alternative investment manager providing debt and equity capital solutions to healthcare and technology companies, including structured venture debt — directly comparable in healthcare-focused debt offerings and patient-capital orientation.
  • Runway Growth Finance: Runway Growth Finance provides senior debt to growth-stage companies across healthcare and technology, often partnering with VC sponsors. Overlapping strategy in growth-stage debt for healthcare companies makes it a direct peer.
  • Trinity Capital: Trinity Capital provides venture debt and equipment financing to growth-stage companies, with a notable healthcare and life sciences vertical. Comparable to K2HV in customer segment (healthcare growth companies) and product (customized debt facilities).

Broad incumbents

  • OrbiMed: OrbiMed is one of the largest global healthcare-dedicated investment firms, offering private equity, credit, and royalty financing across all stages of healthcare and life sciences. Comparable to K2HV in healthcare specialization but operates at significantly broader scale and product breadth.
  • Silicon Valley Bank (First Citizens Bank): SVB was historically the dominant venture debt provider to US startups including healthcare, now operating under First Citizens Bank. Comparable as a broad incumbent in venture debt with significant healthcare exposure, but serves a much wider customer base beyond healthcare.
  • Perceptive Advisors: Perceptive Advisors is a healthcare-focused investment firm managing credit, venture, and public equity strategies. Comparable in healthcare specialization and credit-oriented product offering, though substantially larger and more diversified.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

K2 HealthVentures financial estimates

Financial estimate

Revenue estimate

Valuation estimate

K2 HealthVentures leadership team

Management profile

Number of profiles

Profiles8 records

K2 HealthVentures funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

K2 HealthVentures M&A and investment

M&A and investment

M&A

Investments66 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about K2 HealthVentures

What does K2 HealthVentures do?

K2 HealthVentures provides flexible, long-term financing solutions to innovative private and public companies in the life sciences and healthcare industries. Its primary vehicle is customized debt financings structured with milestone-based tranches tied to clinical, regulatory, and commercial milestones, complemented by the ability to invest in equity and convertible securities under a broad investment mandate.

Is K2 HealthVentures a public or private company?

K2 HealthVentures is a private company. It is classified as unknown and is currently operating.

When was K2 HealthVentures founded?

K2 HealthVentures was founded in 2018. It employs 11 to 50 people.

Where is K2 HealthVentures based?

K2 HealthVentures is headquartered in Boston, United States, in the North America region.

How does K2 HealthVentures make money?

Two revenue lines are on record. Debt Financing Returns are the primary driver. The others are equity Investment Returns.

Who are K2 HealthVentures's main competitors?

Direct peers on record are Horizon Technology Finance, Oxford Finance, Hercules Capital, SLR Capital Partners / SLR Healthcare ABL, Innovatus Capital Partners, Runway Growth Finance and Trinity Capital. Broad incumbents are OrbiMed, Silicon Valley Bank (First Citizens Bank) and Perceptive Advisors.

Does K2 HealthVentures have an API?

No public API is recorded for K2 HealthVentures.

What industry is K2 HealthVentures in?

K2 HealthVentures's product category is Healthcare and Life Sciences Investment Services. Its primary akta.pro industry code is FSANAIAB, Independent Venture Debt Funds / Platforms, with a secondary code of FSANACAD, Business Services (B2B) Growth Equity. Its NAICS code is 525 and its SIC code is 6153.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Venture Capital Access OnlineTech-Enabled Rural Health Care Leader Hopscotch Primary Care Announces $53 Million in Latest Funding RoundHopscotch Primary Care raised $53 million in Series D funding, led by 8VC and Town Hall Ventures. The company serves over 15,000 patients in rural Southeastern U.S. communities and will use the funds to expand into new markets and scale its technology-powered operations.GlobeNewswireCartesian Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business UpdateCartesian Therapeutics reported Q2 2026 net income of $15.8 million and $149.3 million in cash as of June 30, 2026. The company extended its cash runway into 2028 with up to $150 million of non-dilutive financing from K2 HealthVentures. Phase 3 AURORA trial data is expected in Q1 2027, with a BLA planned for mid-2027.Stock TitanCartesian Q2 Earnings: $149.3M Cash, Runway Into 2028Cartesian Therapeutics reported Q2 2026 financial results with approximately $149.3 million in cash, cash equivalents, and restricted cash as of June 30, 2026, supported by a $50 million initial tranche from a credit facility with K2 HealthVentures providing up to $150 million in non-dilutive financing extending runway into 2028. The company reported net income of $15.8 million for the quarter, driven largely by a $49.2 million gain on contingent value rights, while R&D expenses increased to $20.4 million from $14.9 million year-over-year due to the ongoing Phase 3 AURORA trial. Key clinical milestones include data from the Phase 3 AURORA trial expected in Q1 2027 with a BLA filing planned for mid-2027, and a new strategic licensing agreement with WestGene BioPharma for in vivo CAR-T development.Quiver QuantitativeWerewolf Therapeutics Reports Second Quarter 2026 Financial Results and Business Update | HOWL Stock NewsWerewolf Therapeutics reported Q2 2026 financial results, including a $21 million payment from Jazz Pharmaceuticals for the JZP898 program and a net income of $3.7 million, a turnaround from a net loss of $18.0 million in Q2 2025. The company's cash position declined from $46.5 million to $22.0 million during the quarter after repaying all debt obligations to K2 HealthVentures LLC. Werewolf expects to provide updates on its strategic alternatives process and clinical trials later in 2026.Stock TitanWerewolf Therapeutics Q2 2026 Earnings: $3.7M ProfitWerewolf Therapeutics reported Q2 2026 financial results, posting net income of $3.7 million compared to an $18.0 million net loss in Q2 2025, driven by a $21.0 million collaboration revenue from the sale of its JZP898 program to Jazz Pharmaceuticals. The company repaid all amounts owed under its loan agreement with K2 HealthVentures and ended the quarter with $22.0 million in cash, expecting to fund operations into Q2 2027. Werewolf is currently exploring strategic alternatives with Piper Sandler as its exclusive financial advisor.VenturecapitalMighty Therapeutics Secures $150 Million Investment for Growth and DevelopmentMighty Therapeutics Holdings Inc. has secured up to $150 million in non-dilutive growth and equity capital through a credit facility with K2 HealthVentures (up to $125 million) and Series B financing with Morningside ($25 million). The funding extends the company's cash runway into 2028 with projected cash flow positivity expected in early 2029. The capital will support acceleration of launch activities and late-stage development initiatives for the company's mitochondrial medicine pipeline targeting rare and age-related diseases.Pulse 2.0Mighty Therapeutics Secures Up To $150 Million To Advance Mitochondrial Targeted MedicinesMighty Therapeutics announced the closing of financing transactions securing up to $150 million in non-dilutive growth and equity capital, including a $125 million credit facility from K2 HealthVentures and a $25 million Series B initial closing from founding investor Morningside. The financing is designed to support commercial and clinical development of the company's mitochondrial-targeted medicines pipeline for rare and age-related diseases, including dry age-related macular degeneration and polymerase gamma-related mitochondrial disease. The company stated the new resources extend its cash runway into 2028, with subsequent drawdowns under the credit facility expected to support projected cash flow positivity by early 2029.citybizMighty Therapeutics Secures Up to $150 Million to Advance Mitochondrial Medicine PipelineMighty Therapeutics secured up to $150 million in capital from K2 HealthVentures and Morningside to advance its mitochondrial medicine pipeline. The funding supports commercialization of its FDA-approved Barth syndrome therapy and late-stage programs for age-related macular degeneration and Parkinson's disease. Proceeds are expected to fund operations through 2028.MightytxMighty Therapeutics Secures Up to $150 Million to Progress Commercial and Clinical Development of New Class of Mitochondrial Targeted MedicinesMighty Therapeutics closed up to $150 million in non-dilutive capital, including a $125 million credit facility with K2 HealthVentures and a $25 million Series B from Morningside. The funds support commercial and clinical development, with cash runway extending to 2028 and projected cash flow positivity in early 2029.BioSpaceMighty Therapeutics Secures Up to $150 Million to Progress Commercial and Clinical Development of New Class of Mitochondrial Targeted MedicinesMighty Therapeutics closed up to $150 million in non-dilutive capital, including a $125 million credit facility from K2 HealthVentures and a $25 million Series B from Morningside. The funds support its lead commercial product and late-stage development, with cash runway extending to 2028 and projected cash flow positivity in early 2029.